(Reuters) – AstraZeneca Plc said Sunday that it has reviewed people who received the COVID-19 vaccine that showed no evidence of an increased risk of blood clots.
The study covered more than 17 million people vaccinated in the European Union and the United Kingdom.
“A careful review of all available safety data of more than 17 million people vaccinated in the European Union and the UK with AstraZeneca’s COVID-19 vaccine has not shown any evidence of an increased risk. in pulmonary embolism, deep vein thrombosis or thrombocytopenia, at any particular age. group, gender, badge or in any particular country, ”the statement said.
Authorities in Denmark, Norway and Iceland have suspended the use of the vaccine over clotting cases, while Austria stopped using a batch of AstraZeneca photos last week while investigating deaths from coagulation disorders.
Ireland on Sunday suspended the COVID-19 vaccine at AstraZeneca for a period “out of sufficient warning”.
The drug dealer said that further tests have been and are being carried out by the company and the European health authorities and that none of the retests have revealed cause for concern.
There are also no confirmed cases regarding the quality of any of their COVID-19 vaccine arrests used across Europe and the rest of the world, the company said.
Reporting by Radhika Anilkumar in Bengaluru. Edited by Jane Merriman